Quarterly report · Q2
4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.7bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥7.0bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.1bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.3bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥621m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥678m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥623m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥677m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥100.0bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥112.1bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥31.3bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥68.7bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥61.6bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥68.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥61.6bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥21.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥41.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥341m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥48.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥9.83 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥25.29 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.76 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥40.53 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥9.46 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥23.86 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.14 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 68.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥13m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥13m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥338m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥187m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥292m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥292m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥50m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥133m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥38m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥13m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥566m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥7.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥13.7bn |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥7.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥13m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥189m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥99m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥933m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥890m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥192m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥144m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥924m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥485m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥6.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥6.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥126m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥67m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 887
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -390000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -546000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -571000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YTDDuration | -760000000 | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 110000000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 0 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -106000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -122000000 | JPY |
| Increase due to acquisition of consolidated subsidiaries inv cf IFRS | Prior1YTDDuration | 25000000 | JPY |
| Increase due to acquisition of consolidated subsidiaries inv cf IFRS | CurrentYTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -19202000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -2538000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | CurrentYTDDuration | 273000000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | 132000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | -279000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -21494000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -3628000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | 19330000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | 1701000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YTDDuration | -158000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYTDDuration | -264000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 950000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 28000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -570000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -2121000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -406000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -445000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YTDDuration | 29212000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YTDDuration | 279000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | CurrentYTDDuration | 2192000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -564000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -754000000 | JPY |
| Other fin cf IFRS | Prior1YTDDuration | 12000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | 5000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | 48086000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | 341000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YTDDuration | 28273000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYTDDuration | -1261000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 13192000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 22782000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 0 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 0 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 41467000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 21521000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember | 7860000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember | 2439000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember | 1759000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |